Trial Profile
A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWER-Lung 1
- Sponsors Regeneron Pharmaceuticals
- 24 Oct 2023 Results of exploratory sub group analysis (from studies EMPOWER-Lung 1 and EMPOWER-Lung 3) of pts with squamous NSCLC treated with cemiplimab presented at the 48th European Society for Medical Oncology Congress
- 15 Oct 2023 According to a Regeneron Pharmaceuticals media release, subgroup analysis data for EMPOWER-Lung 1 and 3, will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 to 24 in Madrid, Spain.
- 12 Sep 2023 Results of pool analysis (EMPOWER-Lung 1 , EMPOWERLung 3) assessing pharmacokinetics of cemiplimab , presented at 2023 American College of Clinical Pharmacology Annual Meeting.